Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase II open-label study of 迈粒生® (albipagrastim alfa) in pediatric solid tumors
CTR20262897Phase 2Active
- Sponsor
- Qilu Pharmaceutical
- Start
- Sep 2026
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of rHSA-GCSF in febrile neutropenia (FN), chemotherapy-induced neutropenia (CIN), sponsored by Qilu Pharmaceutical. Started Sep 2026; status: active.
02
Drugs
rHSA-GCSF
03
Conditions
febrile neutropenia (FN)chemotherapy-induced neutropenia (CIN)
Beyond the preview
Go deeper on CTR20262897.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262897.